MAGLUMI
SARS-CoV-2 S-RBD IgG (CLIA)
The fully automated quantitative
serology test to detect IgG antibodies against S-RBD
(the receptor-binding domain of S protein)
Significance of S- RBD Antibody Detection
A coronavirus contains four structural proteins, including spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins. The S protein mediates viral entry into host cells by first binding to a host receptor through the receptor-binding domain (RBD) in the S1 subunit and then fusing the viral and host membranes through the S2 subunit. SARS-CoV-2 recognizes ACE2 as its host receptor binding to viral S protein. Therefore, it is critical to define the RBD in SARS-CoV-2 S protein as the most likely target for the development of virus attachment inhibitors, neutralizing antibodies, and vaccines [2].
Correlates well with COVID-19 Neutralizing antibodies which reflects the COVID-19 patients’ immunity
Results in less than
30 minutes
Single make kits
for all Maglumi
models
Excellent performance:
Sensitivity -100%
Specificity 99.6%
Small sample volume
of 10 microl
Flexible pack
size of 100 tests
and 50 tests
2 level controls and
calibrators provided
alongwith kit- No need
to purchase extra
Sample type-
Serum/Plasma
Wide Linearity range
of 0.18- 100 AU/ml
Onboard Stability
of 6 weeks
Maglumi 600
Maglumi 800
Maglumi 2000
Maglumi Offers Complete COVID- 19
Testing Solution Assays
D-Dimer
COVID-19 IgM
COVID-19 IgG
CRP
PCT
IL-6
CK-MB
Troponin I
Myoglobin
hs-cTn I
H-FABP
NT-proBNP
β2-MG
Albumin
Contact us for demo and best offer price